Outcomes after autologous SCT in lymphoma patients grouped by weight.

about

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation.

P2860

Q36580547-700B13B2-5B15-4CD5-8BD8-C6808195C229

P2860

Outcomes after autologous SCT in lymphoma patients grouped by weight.

Item

http://www.wikidata.org/entity/Q47406671

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Outcomes after autologous SCT in lymphoma patients grouped by weight.

@en

Outcomes after autologous SCT in lymphoma patients grouped by weight.

@nl

type

Item

label

Outcomes after autologous SCT in lymphoma patients grouped by weight.

@en

Outcomes after autologous SCT in lymphoma patients grouped by weight.

@nl

prefLabel

Outcomes after autologous SCT in lymphoma patients grouped by weight.

@en

Outcomes after autologous SCT in lymphoma patients grouped by weight.

@nl

P1476

Outcomes after autologous SCT in lymphoma patients grouped by weight.

@en

P2093

B T Hill

http://www.w3.org/2001/XMLSchema#string

C M Wenzell

http://www.w3.org/2001/XMLSchema#string

C Weber

http://www.w3.org/2001/XMLSchema#string

J E Lau

http://www.w3.org/2001/XMLSchema#string

K D Carlstrom

http://www.w3.org/2001/XMLSchema#string

L A Rybicki

http://www.w3.org/2001/XMLSchema#string

M Earl

http://www.w3.org/2001/XMLSchema#string

M Kalaycio

http://www.w3.org/2001/XMLSchema#string

N S Majhail

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010

Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group.

Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults

Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing.

Chemotherapy dosing part I: scientific basis for current practice and use of body surface area.

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.

Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA).

Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey.

Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.

Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.

P2888

bmt.2014.327

P304

652-657

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2014.327

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25665041

http://www.w3.org/2001/XMLSchema#string

Outcomes after autologous SCT in lymphoma patients grouped by weight.

about

P2860

P2860

Outcomes after autologous SCT in lymphoma patients grouped by weight.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P698